IL132503A - The use of tyrosine inhibitors in the preparation of a drug that prevents the production of melanin in the melanocytes of the iris, which is caused by prostaglandin derivatives - Google Patents

The use of tyrosine inhibitors in the preparation of a drug that prevents the production of melanin in the melanocytes of the iris, which is caused by prostaglandin derivatives

Info

Publication number
IL132503A
IL132503A IL13250398A IL13250398A IL132503A IL 132503 A IL132503 A IL 132503A IL 13250398 A IL13250398 A IL 13250398A IL 13250398 A IL13250398 A IL 13250398A IL 132503 A IL132503 A IL 132503A
Authority
IL
Israel
Prior art keywords
latanoprost
tyrosine
melanin production
methyl
iris
Prior art date
Application number
IL13250398A
Other languages
English (en)
Hebrew (he)
Other versions
IL132503A0 (en
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of IL132503A0 publication Critical patent/IL132503A0/xx
Publication of IL132503A publication Critical patent/IL132503A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13250398A 1997-04-22 1998-04-21 The use of tyrosine inhibitors in the preparation of a drug that prevents the production of melanin in the melanocytes of the iris, which is caused by prostaglandin derivatives IL132503A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI000939A IT1291633B1 (it) 1997-04-22 1997-04-22 Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
PCT/EP1998/002365 WO1998047515A1 (en) 1997-04-22 1998-04-21 THE USE OF α-METHYL-P-TYROSINE TO INHIBIT MELANIN PRODUCTION IN IRIS MELANOCYTES

Publications (2)

Publication Number Publication Date
IL132503A0 IL132503A0 (en) 2001-03-19
IL132503A true IL132503A (en) 2004-06-20

Family

ID=11376994

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13250398A IL132503A (en) 1997-04-22 1998-04-21 The use of tyrosine inhibitors in the preparation of a drug that prevents the production of melanin in the melanocytes of the iris, which is caused by prostaglandin derivatives

Country Status (22)

Country Link
US (1) US6359001B1 (no)
EP (1) EP0977575B1 (no)
JP (1) JP2001521540A (no)
KR (1) KR20010020202A (no)
CN (1) CN1255064A (no)
AT (1) ATE227577T1 (no)
AU (1) AU732046B2 (no)
CA (1) CA2287887A1 (no)
DE (1) DE69809408T2 (no)
DK (1) DK0977575T3 (no)
ES (1) ES2187028T3 (no)
HU (1) HUP0002100A3 (no)
IL (1) IL132503A (no)
IT (1) IT1291633B1 (no)
NO (1) NO995122L (no)
NZ (1) NZ500435A (no)
PL (1) PL189304B1 (no)
PT (1) PT977575E (no)
RU (1) RU2218159C2 (no)
SI (1) SI0977575T1 (no)
SK (1) SK284255B6 (no)
WO (1) WO1998047515A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1159266B1 (en) 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
WO2011011065A1 (en) * 2009-07-22 2011-01-27 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US9744237B2 (en) * 2009-01-29 2017-08-29 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US20110280909A1 (en) * 2009-01-29 2011-11-17 Kambiz Thomas Moazed Method and system for effecting changes in pigmented tissue
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
CA2862689C (en) * 2012-01-17 2020-03-10 Tyme, Inc. .alpha.-methyl-dl-tyrosine, compositions, kits, combinations and use thereof for the treatment of cancer or for reducing cell proliferation
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US10813901B2 (en) 2013-10-22 2020-10-27 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9763903B2 (en) 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US10751313B2 (en) 2013-10-22 2020-08-25 Yamo Pharmaceuticals Llc Compositions and methods for treating autism
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
ES2738248B2 (es) * 2018-06-21 2023-03-10 Consejo Superior Investigacion Uso de inhibidores de la tirosina hidroxilasa para el tratamiento del aneurisma de aorta
MX2021013901A (es) 2019-05-14 2022-04-12 Tyme Inc Composiciones y métodos para el tratamiento del cáncer.
CN116035151A (zh) * 2023-01-18 2023-05-02 云南贝泰妮生物科技集团股份有限公司 一种刺梨闪释粉及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04117313A (ja) * 1990-09-06 1992-04-17 Kanebo Ltd 美白化粧料

Also Published As

Publication number Publication date
ITMI970939A1 (it) 1998-10-22
RU2218159C2 (ru) 2003-12-10
EP0977575B1 (en) 2002-11-13
WO1998047515A1 (en) 1998-10-29
DE69809408D1 (de) 2002-12-19
AU732046B2 (en) 2001-04-12
CA2287887A1 (en) 1998-10-29
CN1255064A (zh) 2000-05-31
EP0977575A1 (en) 2000-02-09
HUP0002100A2 (hu) 2000-11-28
ES2187028T3 (es) 2003-05-16
ATE227577T1 (de) 2002-11-15
NO995122L (no) 1999-12-21
NZ500435A (en) 2001-09-28
HUP0002100A3 (en) 2003-05-28
SK284255B6 (sk) 2004-12-01
PL189304B1 (pl) 2005-07-29
US6359001B1 (en) 2002-03-19
JP2001521540A (ja) 2001-11-06
DE69809408T2 (de) 2003-07-10
KR20010020202A (ko) 2001-03-15
DK0977575T3 (da) 2003-03-10
PT977575E (pt) 2003-03-31
AU7646298A (en) 1998-11-13
SK142499A3 (en) 2000-09-12
IL132503A0 (en) 2001-03-19
ITMI970939A0 (no) 1997-04-22
IT1291633B1 (it) 1999-01-11
NO995122D0 (no) 1999-10-21
PL336386A1 (en) 2000-06-19
SI0977575T1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
IL132503A (en) The use of tyrosine inhibitors in the preparation of a drug that prevents the production of melanin in the melanocytes of the iris, which is caused by prostaglandin derivatives
EP1441697B1 (en) Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
AU775575B2 (en) Conductance of improperly folded proteins through the secretory pathway
WO1997025042A8 (en) Use of an agonist of ppar-alpha and ppar-gamma for the treatment of syndrom x
JP2008260782A (ja) 神経細胞機能の維持、その消失の防止又は回復のためのデプレニル化合部を利用した器具
Shenfeld et al. Rapid effects of estrogen and progesterone on tone and spontaneous rhythmic contractions of the rabbit bladder
Bennett et al. Chronic sodium azide treatment impairs learning of the Morris water maze task
Hatta et al. Melanin monomers within coated vesicles and premelanosomes in melanin synthesizing cells
Lamers et al. Multihormonal control of enzyme clusters in rat liver ontogenesis II. Role of glucocorticosteroid and thyroid hormone and of glucagon and insulin
CA2349427A1 (en) Method for preventing increased iridial pigmentation during prostaglandin treatment
SI9720060A (sl) Uporaba 2-fenil-1,2-benzizoselenazol-3(2H)-ona za pripravo farmacevtskega pripravka za zdravljenje Alzheimerjeve bolezni
Denda et al. Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats.
Lantos Development of nitrosourea-induced brain tumours—with a special note on changes occurring during latency
Jakobsen et al. Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP+ toxicity by GDNF
Regnault et al. Effect of encapsulation on the anti-inflammatory properties of superoxide dismutase after oral administration
Fernstrom et al. In vivo tyrosine hydroxylation in the diabetic rat retina: effect of tyrosine administration
Owen et al. Effect of chronic amphetamine administration on central dopaminergic mechanisms in the vervet
EP0489846A1 (en) Antisense oligonucleotides to c-abl proto-oncogene
Gnoni et al. Mechanism of triiodothyronine stimulation on microsomal fatty acid chain elongation synthesis in rat liver
AU7500398A (en) Ganglioside gm3 induced apoptosis of neural cells
Murakami et al. Regulation of nerve growth factor secretion in LM cells by catechol derivatives
US20100094061A1 (en) Stat3 phosphorylation inhibitor and notch1 expression inhibitor
Parke et al. The biochemical pharmacology of mucus
CZ372099A3 (cs) Použití alfa-methyl-p-tyrosinu k inhibici produkce melaninu v pigmentových buňkách duhovky
GB2595633A (en) Anti-infective agents

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees